A Phase 3 interventional study of GC5107 in Primary Immune Deficiency, sponsored by GC Biopharma Corp. Active, not recruiting at 8 sites in 3 countries. Open to participants aged 2 Years to 16 Years. Per ClinicalTrials.gov, last updated 2025-07-25.
Sponsored by GC Biopharma Corp · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 108 studies in Primary Immunodeficiency Diseases with a site in United States — 25 open to participants now, 35 under way, 4 of them phase 3. Primary Immunodeficiency Diseases · United States.
Among the 108 studies in Primary Immunodeficiency Diseases with a site in United States, this one is the 52nd largest by planned enrollment of the 75 interventional ones that give a count, is one of 9 that started in 2020, is one of 30 in phase 3, reaches primary completion later than 3 of the 29 other live ones, and was the 84th registered.
211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.
Browse Primary Immunodeficiency Diseases studies →25 of the 108 studies in Primary Immunodeficiency Diseases with a site in United States are open now. Recruiting first, the newest first:
Yale University · Sites in United States
Ages 18–65
University of California, San Francisco · Sites in United States
Shwachman-Diamond Syndrome Alliance Inc · Sites in United States
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 2–120 · Healthy volunteers
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–75 · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.
This study: 2 Years to 16 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
108 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 26 · Phase 3 34 · Phase 4 8
First in 1991; this study’s year is marked. 9 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 36 across 125 interventional studies indexed under Primary Immunodeficiency Diseases.
Median enrollment 40 across the 75 interventional studies, 343 across the 31 observational. Of the 64 that completed or were terminated, 38 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 108 have an industry lead sponsor. The 10 most frequent:
This study is registered under GC Biopharma Corp, one of the names counted as GC Biopharma Corp.. Under that name alone:
GC Biopharma Corp is the lead sponsor of 16 studies on the registry; 6 are open to participants now.
GC Biopharma Corp. has 3 studies filed under Primary Immunodeficiency Diseases — fewer than ten, so there is no comparison to draw.
11 of the studies in Primary Immunodeficiency Diseases with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04640142Phase 3OctapharmaStudy to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases | 2026-11 |
| NCT04944979Phase 3Kedrion S.p.A.Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10) | 2026-12 |
| NCT01962415Paul SzabolcsReduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT | 2026-11 |
| NCT03266627New York Medical CollegeAdenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection | 2026-12-31 |
| NCT03266640New York Medical CollegeVirus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV) | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 108 studies in Primary Immunodeficiency Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the pharmacokinetics and safety of Immune Globulin Intravenous (Human) GC5107 in pediatric subjects with Primary Humoral Immunodeficiency (PHID).
This is a prospective, open-label, single-arm, historically controlled, multi-center Phase III study to assess the pharmacokinetics and safety of Immune Globulin Intravenous (Human) GC5107 in pediatric subjects aged ≥ 2 years and \< 17 years with PHID.
Subjects will receive intravenous infusions of the investigational product at the same dose and interval as used for their previous Immunoglobulin intravenous (IGIV) maintenance therapy. GC5107 will be infused every 21 or 28 days for a period of 12 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immune Globulin Intravenous (Human), 10% Liquid
Biological: GC5107
Intravenously infused at a dose of 300 - 900 mg per kg (of body weight) every 21 or 28 days for 12 months
Also known as: GCC 10% IGIV, Immune Globulin Intravenous (Human), 10% Liquid
The Pharmacokinetic (PK) Plasma concentration-time curve of total IgG
Time frame: before and after 5th infusion (12 or 16 weeks)
The Pharmacokinetic (PK) Half-life of total IgG
Time frame: before and after 5th infusion (12 or 16 weeks)
The Pharmacokinetic (PK) Area under the curve of total IgG
Time frame: before and after 5th infusion (12 or 16 weeks)
The Pharmacokinetic (PK) Volume of distribution of total IgG
Time frame: before and after 5th infusion (12 or 16 weeks)
The Pharmacokinetic (PK) Maximum concentration of total IgG
Time frame: before and after 5th infusion (12 or 16 weeks)
The Pharmacokinetic (PK) Minimum concentration of total IgG
Time frame: before and after 5th infusion (12 or 16 weeks)
The Pharmacokinetic (PK) Time of maximum concentration of total IgG
Time frame: before and after 5th infusion (12 or 16 weeks)
The Pharmacokinetic (PK) Clearance of total IgG
Time frame: before and after 5th infusion (12 or 16 weeks)
Trough serum total IgG levels before each infusion of GC5107 in all subjects and the interval between infusions
Time frame: 12 months
The proportion of infusions with temporally associated adverse events (AEs) that occur during or within 1 hour, 24 hours, and 72 hours following an infusion of investigational product
AEs that occur during or within 1 hour, 24 hours, and 72 hours following each infusion during 12 months of the study period
Time frame: 12 months
The Pharmacokinetic (PK) Maximum concentration of IgG subclasses
Time frame: before and after 5th infusion (12 or 16 weeks)
The Pharmacokinetic (PK) Minimum concentration of IgG subclasses
Time frame: before and after 5th infusion (12 or 16 weeks)
The Pharmacokinetic (PK) Half-life of IgG subclasses
Time frame: before and after 5th infusion (12 or 16 weeks)
Trough serum level of IgG subclasses and specific IgG antibodies before Infusion 1 and 13 (for subjects on 28-day infusion schedule) or Infusion 1 and 17 (for subjects on 21-day infusion schedule)
Time frame: 12 months
Number and proportion of subjects who failed to meet the target IgG trough level (500 mg/dL) at any time point equal to or subsequent to 5th infusion (estimated 5 half-lives)
Time frame: 12 months
The overall incidence of all AEs that occur during or within 1 hour, 24 hours, and 72 hours following an infusion of investigational product
AEs that occur during or within 1 hour, 24 hours, and 72 hours following each infusion during 12 months of the study period
Time frame: 12 months
The frequency of all AEs that occur during the study regardless of the investigator's assessment of their relationship to investigational product
Time frame: 13 months (12 months of treatment + 1 month of follow-up)
The frequency of suspected adverse reactions as defined by all AEs either classified as at least possibly related to GC5107
Time frame: 13 months (12 months of treatment + 1 month of follow-up)
The number and proportion of GC5107 infusions for which the infusion rate was decreased due to AEs
Time frame: 12 months
The proportion of AEs considered by the investigator to be investigational product related
Time frame: 13 months (12 months of treatment + 1 month of follow-up)
Viral safety (freedom from transmission of blood-borne viral diseases): the human immunodeficiency virus (HIV) type 1 & 2, hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), and parvovirus B19
Time frame: 13 months (12 months of treatment + 1 month of follow-up)
The incidence of acute serious bacterial infections (aSBIs) defined at United States Food and Drug Administration (FDA) guidance criteria (bacterial pneumonia, bacteremia/sepsis, bacterial meningitis, visceral abscess, osteomyelitis/septic arthritis)
Time frame: 13 months (12 months of treatment + 1 month of follow-up)
The incidence of infections other than acute serious bacterial infections
Time frame: 13 months (12 months of treatment + 1 month of follow-up)
The number of days missed from work, school, kindergarten, day care or days unable to perform normal daily activities due to infections
Time frame: 13 months (12 months of treatment + 1 month of follow-up)
The number of days that the care provider of the pediatric subject had to miss work in order to care for the child due to infections
Time frame: 13 months (12 months of treatment + 1 month of follow-up)
The number of days of unscheduled physician visits due to infection
Time frame: 13 months (12 months of treatment + 1 month of follow-up)
The number of days of hospitalizations due to infection
Time frame: 13 months (12 months of treatment + 1 month of follow-up)
The number of days of intravenous (IV) therapeutic antibiotics
Time frame: 13 months (12 months of treatment + 1 month of follow-up)
The number of days of oral (PO) therapeutic antibiotics
Time frame: 13 months (12 months of treatment + 1 month of follow-up)
Time to resolution of infections
Time frame: 13 months (12 months of treatment + 1 month of follow-up)
The incidence of infections by trough IgG levels
Time frame: 13 months (12 months of treatment + 1 month of follow-up)
Episodes of fever (annual rate of fever episodes per subject)
Time frame: 13 months (12 months of treatment + 1 month of follow-up)
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2020 (actual). Primary completion is estimated for May 2026, 65 months after the start.
Of 25 phase 3 interventional studies under Primary Immunodeficiency Diseases, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 41. This study's planned 65 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Primary Immunodeficiency Diseases →